These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27193748)

  • 1. A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.
    Ofotokun I; Titanji K; Lahiri CD; Vunnava A; Foster A; Sanford SE; Sheth AN; Lennox JL; Knezevic A; Ward L; Easley KA; Powers P; Weitzmann MN
    Clin Infect Dis; 2016 Sep; 63(5):663-671. PubMed ID: 27193748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial.
    Ofotokun I; Collins LF; Titanji K; Foster A; Moran CA; Sheth AN; Lahiri CD; Lennox JL; Ward L; Easley KA; Weitzmann MN
    Clin Infect Dis; 2020 Oct; 71(7):1655-1663. PubMed ID: 31621838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
    Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
    Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
    Eastell R; Black DM; Boonen S; Adami S; Felsenberg D; Lippuner K; Cummings SR; Delmas PD; Palermo L; Mesenbrink P; Cauley JA;
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3215-25. PubMed ID: 19567517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
    Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration.
    Carvas JS; Pereira RM; Caparbo VF; Fuller P; Silveira CA; Lima LA; Bonfa E; Mello SB
    Osteoporos Int; 2010 Oct; 21(10):1723-9. PubMed ID: 19997905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM; Reid IR; Boonen S; Bucci-Rechtweg C; Cauley JA; Cosman F; Cummings SR; Hue TF; Lippuner K; Lakatos P; Leung PC; Man Z; Martinez RL; Tan M; Ruzycky ME; Su G; Eastell R
    J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
    Crawford BA; Kam C; Pavlovic J; Byth K; Handelsman DJ; Angus PW; McCaughan GW
    Ann Intern Med; 2006 Feb; 144(4):239-48. PubMed ID: 16490909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
    Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
    J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study.
    Eastell R; Boonen S; Cosman F; Reid IR; Palermo L; Cummings SR; Black DM
    J Bone Miner Res; 2015 Mar; 30(3):570-4. PubMed ID: 25214069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
    Huang J; Meixner L; Fernandez S; McCutchan JA
    AIDS; 2009 Jan; 23(1):51-7. PubMed ID: 19050386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM; Reid IR; Cauley JA; Cosman F; Leung PC; Lakatos P; Lippuner K; Cummings SR; Hue TF; Mukhopadhyay A; Tan M; Aftring RP; Eastell R
    J Bone Miner Res; 2015 May; 30(5):934-44. PubMed ID: 25545380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
    Hershman DL; McMahon DJ; Crew KD; Cremers S; Irani D; Cucchiara G; Brafman L; Shane E
    J Clin Oncol; 2008 Oct; 26(29):4739-45. PubMed ID: 18711172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture.
    Zhu K; Zhang J; Zhang C; Zhao Z; Gao J; Li X; Xia X; Xu X; Zhang T; Guan J
    Osteoporos Int; 2021 Mar; 32(3):559-564. PubMed ID: 32989470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.